ClinicalTrials.gg

Program

difamilast

Also written as “OPA-15406”, “1% OPA-15406 Ointment” and “0.3% OPA-15406 Ointment”.

Its studies are mostly in Dermatitis, Atopic, led by 3 companies.

Furthest: phase 3, since Apr 7, 201916 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsuka132 open or runningphase 3since Apr 7, 2019Oct 3, 2012Dec 2026phase 3 · NCT07173478
Aurobindo Pharma20 open or runningphase 3since Oct 5, 2022Oct 5, 2022none ahead
Eurofarma Laboratorios10 open or runningphase 2since Oct 21, 2016Oct 21, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 3, 2012First study: phase 1 study in Dermatitis, AtopicNew to OtsukaOtsuka · NCT01702181 · 92 enrolled · United States
  2. Feb 19, 2014Phase 2 study in Dermatitis, AtopicOtsuka · NCT02068352 · 121 enrolled · United States, Australia, Poland
  3. Jan 5, 2015Phase 1 study in Dermatitis, AtopicOtsuka · NCT02334787 · 32 enrolled · Japan
  4. Sep 8, 2016Phase 2 study in Dermatitis, AtopicOtsuka · NCT02914548 · 200 enrolled · Japan
  5. Oct 21, 2016Eurofarma Laboratorios's first study: phase 2 study in Dermatitis, AtopicNew to Eurofarma LaboratoriosEurofarma Laboratorios · NCT02945657 · 32 enrolled · United States, Honduras, Panama
  6. Jan 6, 2017Phase 2 study in Dermatitis, AtopicOtsuka · NCT03018691 · 73 enrolled · Japan
  7. Apr 7, 20193 phase 3 studies in Dermatitis, AtopicOtsuka · NCT03908970, NCT03911401, NCT03961529
  8. May 9, 2022Phase 3 study in Dermatitis, AtopicOtsuka · NCT05372653 · 41 enrolled · Japan
  9. Oct 5, 2022Aurobindo Pharma's first study: phase 3 study in Dermatitis, AtopicNew to Aurobindo PharmaAurobindo Pharma · NCT05571943 · 542 enrolled · United States
  10. Nov 1, 2022Phase 3 study in Dermatitis, AtopicAurobindo Pharma · NCT05608343 · 153 enrolled · United States
  11. Dec 2, 20222 phase 3 studies in Dermatitis, AtopicOtsuka · NCT05667623, NCT05650320
  12. Sep 7, 20252 phase 3 studies in Dermatitis, AtopicOtsuka · NCT07173478, NCT07184645

Ahead

  1. Dec 2026Primary completion: phase 3 study in Dermatitis, AtopicOtsuka · NCT07173478
  2. Feb 2027Primary completion: phase 3 study in Dermatitis, AtopicOtsuka · NCT07184645

TargetBeta

“Phosphodiesterase 4 inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
RoflumilastruleAstraZenecaphase 461
apremilastruleAmgenphase 448
ensifentrineruleMerckphase 317
tanimilastruleChiesi Farmaceuticiphase 315

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07184645Dermatitis, Atopic · Japan3Not yet recruitingOtsukaFeb 2027198
NCT07173478Dermatitis, Atopic · Japan3Not yet recruitingOtsukaDec 2026156
NCT05650320Dermatitis, Atopic · China3CompletedOtsukaJul 21, 2024240
NCT05667623Dermatitis, Atopic · China3CompletedOtsukaJun 17, 2024270
NCT05608343Dermatitis, Atopic · United States3CompletedAurobindo PharmaOct 27, 2023153
NCT05571943Dermatitis, Atopic · United States3CompletedAurobindo PharmaJul 31, 2024542
NCT05372653Dermatitis, Atopic · Japan3CompletedOtsukaDec 29, 202241
NCT03961529Dermatitis, Atopic · Japan3CompletedOtsukaNov 11, 2020366
NCT03911401Dermatitis, Atopic · Japan3CompletedOtsukaDec 13, 2019251
NCT03908970Dermatitis, Atopic · Japan3CompletedOtsukaDec 28, 2019364
NCT03018691Dermatitis, Atopic · Japan2CompletedOtsukaJun 201773
NCT02945657Dermatitis, Atopic · United States, Honduras, Panama2CompletedEurofarma LaboratoriosJun 8, 201732
NCT02914548Dermatitis, Atopic · Japan2CompletedOtsukaJun 2017200
NCT02334787Dermatitis, Atopic · Japan1CompletedOtsukaFeb 201532
NCT02068352Dermatitis, Atopic · United States, Australia, Poland2CompletedOtsukaJan 28, 2015121
NCT01702181Dermatitis, Atopic · United States1CompletedOtsukaDec 201392

How it is read

Names in the registry

  • “OPA-15406”, 7 entries
  • “1% OPA-15406 Ointment”, 3 entries
  • “0.3% OPA-15406 Ointment”, 2 entries
  • “Difamilast”, 2 entries
  • “1% OPA-15406”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.